Wells Fargo & Company Clene Inc. Transaction History

Wells Fargo & Company

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$0.28 - $0.53 $3 - $6	12 Added 1.66%	733 $0
Q4 2023 Feb 09, 2024	BUY	$0.26 - $0.55 $9 - $20	37 Added 5.41%	721 $0
Q3 2023 Nov 13, 2023	BUY	$0.46 - $0.87 $205 - $388	447 Added 188.61%	684 $0
Q2 2023 Aug 15, 2023	BUY	$0.78 - $1.22 $17 - $28	23 Added 10.75%	237 $0
Q1 2023 May 12, 2023	BUY	$0.95 - $1.62 $2 - $4	3 Added 1.42%	214 $0
Q4 2022 Feb 13, 2023	BUY	$0.92 - $40.2 $70 - $3,095	77 Added 57.46%	211 $0
Q3 2022 Nov 14, 2022	SELL	$0.33 - $73.0 $3 - $730	-10 Reduced 6.94%	134 $0
Q2 2022 Aug 12, 2022	SELL	$2.1 - $4.12 $46,729 - $91,678	-22,252 Reduced 99.36%	144 $0
Q1 2022 May 16, 2022	BUY	$2.42 - $4.42 $26,019 - $47,523	10,752 Added 92.34%	22,396 $88,000
Q4 2021 Feb 14, 2022	SELL	$3.95 - $7.53 $34,254 - $65,300	-8,672 Reduced 42.69%	11,644 $48,000
Q3 2021 Nov 15, 2021	BUY	$6.83 - $13.58 $49,968 - $99,351	7,316 Added 56.28%	20,316 $138,000
Q2 2021 Aug 16, 2021	BUY	$6.98 - $13.33 $89,825 - $171,543	12,869 Added 9823.66%	13,000 $146,000
Q1 2021 May 13, 2021	BUY	$6.39 - $16.3 $837 - $2,135	131 New	131 $2,000

230K

25K

Ticker CLNN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 63,502,000
Market Cap $273M
Description
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral scleros...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.